Mirati Therapeutics, Inc. (MRTX) [Rocket]

In millions, except per share items	Jun-30-23	Mar-31-23	Dec-31-22	Sep-30-22	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21
	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Net income	-176.9	-184.6	-202.5	-173.6	-176.4	-188.4	-199.6	-80.1
Depreciation and amortization [+]	1.1	1.1	0.9	0.7	0.7	0.6	0.6	0.5
Depreciation	1.1	1.1	0.9	0.7	0.7	0.6	0.6	0.5
Stock-based compensation	39.4	47.0	61.6	43.0	38.7	42.9	33.9	26.9
Change in working capital [+]	13.2	-46.7	215.0	1.7	-10.0	-22.0	172.2	5.4
Accounts receivable	-4.3	-5.4	-0.9
Inventories	-4.8	-0.8	-3.0
Other current assets	6.7	-5.7	3.6	-3.2	-5.0		0.8	64.1
Other	15.6	-34.8	215.3	4.9	-5.0	-22.0	171.4	-58.7
Other operating activities	-8.2	-6.9	-203.8	-9.7	3.5	6.4	-145.0	0.2
Cash from operations	-131.4	-190.2	-128.8	-137.8	-143.5	-160.5	-138.0	-47.0

Capital expenditures	-0.7	-0.3	-0.8	-1.2	-1.7	-1.1	-2.6	-2.0
Purchases of property and equipment	-0.7	-0.3	-0.8	-1.2	-1.7	-1.1	-2.6	-2.0
Other cash from investing	16.3	195.4	60.1	15.2	104.7	50.7	-168.2	2.7
Cash from investing	15.5	195.2	59.3	13.9	103.0	49.6	-170.8	0.7

Issuance of common stock, net				155.0			474.7
Option exercises	3.3		8.9		1.0		26.8
Other cash from financing	7.2	1.7	14.8	2.1	2.4	2.5	31.4	8.2
Cash from financing	3.8	1.7	5.9	157.1	1.4	2.5	479.3	8.2

Free cash flow	-132.1	-190.5	-129.6	-139.0	-145.2	-161.6	-140.6	-49.0
Per share (diluted)	($2.27)	($3.28)	($2.30)	($2.47)	($2.61)	($2.91)	($2.71)	($0.95)